Poging GOUD - Vrij
When is the ‘right’ time to quit your job?
Mint Hyderabad
|October 13, 2025
If you leave a job too early, you risk looking impatient. On the other hand, staying too long can lead to stagnation, burnout or resentment
By Thursday afternoon, Rohit Sharma already knew how his Friday would end. The content lead at a Mumbai-based advertising agency would be on back-to-back calls, clearing last-minute escalations, and logging off exhausted well past 9pm. The weekend offered little respite. By Sunday evening, the familiar heaviness returned. “I stopped recognizing myself,” the 38-year-old says. “I was snappy with my team, perpetually tired, and constantly thinking about quitting. But I was also scared of what would happen if I did.”
Across the country in Bengaluru, Ananya Nair faced a different dilemma. For the 34-year-old brand manager at a global FMCG company, everything was “right” on paper: a good salary, a swanky office, and international work trips. Yet, she felt hollow. She recalls, “I would sit in meetings wondering why I was even there. The only time I felt alive was on weekends, cooking and filming recipes for Instagram.
Two professionals, two very different jobs. Both confronting the same question: Had their roles run their course?
The decision to quit is one of the hardest career decisions to make. If you leave too early, you risk looking impatient. On the other hand, staying too long can lead to stagnation, burnout, or resentment.
For most, the decision to quit doesn’t arise from a single bad day. It’s the result of a slow accumulation of fatigue, frustration, and disconnection. Overwork is often the first sign.
Sharma recalls waking up each morning dreading the day ahead; not because of one impossible boss or multiple deadlines, but because the rhythm of his work had become unsustainable. “I wasn’t performing badly,” he says, “but I was permanently exhausted.”
Dit verhaal komt uit de October 13, 2025-editie van Mint Hyderabad.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Mint Hyderabad
Mint Hyderabad
Nvidia, Eli Lilly to invest $1 bn in AI lab
Nvidia Corp. plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., aiming to speed up the use of artificial intelligence (AI) in the pharmaceutical industry.
1 min
January 13, 2026
Mint Hyderabad
Shadowfax IPO to open next week
Logistics services provider Shadowfax is set to launch its ₹1,900-crore initial public offering (IPO) next week, targeting a valuation of ₹7,400 crore, people familiar with the matter said on Monday.
1 min
January 13, 2026
Mint Hyderabad
The US climate cop-out should galvanize others
America's withdrawal from the global battle against climate change is a signal for the rest of the world to unite for the greater good. The cause is vital, not the participation of the US
2 mins
January 13, 2026
Mint Hyderabad
Toyota pushes for fuel norm clarity
The government should soon come out with the final notification for the next phase of India’s Corporate Average Fuel Efficiency standards so that the industry can prepare accordingly, according to a senior Toyota Kirloskar Motor executive.
1 min
January 13, 2026
Mint Hyderabad
Food effect lifts Dec CPI inflation
India's retail inflation rose for the second successive month in December, data released by the statistics ministry on Monday showed, driven by a moderation in negative food inflation and an uptick in core inflation.
1 min
January 13, 2026
Mint Hyderabad
Commissions trump advice in wealth management biz
surge on rising affluence, strong economic growth, higher foreign direct investments, and the growth of the startup ecosystem.
2 mins
January 13, 2026
Mint Hyderabad
The Chinese company taking on the world's memory-chip giants
As AI demand drives prices up, CXMT beats Washington's curbs to vie with Micron and South Korean leaders
4 mins
January 13, 2026
Mint Hyderabad
HC lifts ban on Zydus cancer biosimilar till patent expiry
In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.
2 mins
January 13, 2026
Mint Hyderabad
Fix GST on capital goods to revive private investment
India faces a paradox today.
3 mins
January 13, 2026
Mint Hyderabad
Feeling tired? It could be too many messages
The cumulative stress of constant notifications is leaving many emotionally burnt out. Tackling it requires small, sustainable changes
4 mins
January 13, 2026
Listen
Translate
Change font size
